Core Viewpoint - Nissin Foods Holdings is investing TL1.59 billion ($38.1 million) to establish a subsidiary in Turkey for noodle production, marking a strategic re-entry into the Turkish market with plans for regional expansion [1][2]. Group 1: Investment and Expansion - The investment will include the acquisition of a factory in Sakarya province, along with production equipment and fixed assets [2]. - The company aims to expand sales of instant noodles in Turkey and neighboring regions, including Central Asia, the Middle East, and North Africa [2]. Group 2: Strategic Goals - This initiative is part of Nissin Foods' mid-to-long-term strategy through to 2030, which aims to generate approximately 45% of its core operating profit from overseas markets [2]. - The company has already achieved its previous international growth goals and is committed to further strengthening its focus on international markets [3]. Group 3: Financial Performance - For the fiscal year ending March 31, Nissin Foods reported sales of Y776.5 billion ($5.2 billion), a 6% increase year-over-year [3]. - The core operating profit rose 3.6% to Y83.6 billion, while operating profit increased by 1.4% to Y74.4 billion [3]. - However, the company experienced a decline in key metrics in the first quarter of the new fiscal year, with sales down 4.3% to Y177 billion and core operating profit dropping 25.5% to Y17.4 billion [4].

Core Points - Vivos Inc. has authorized the formation of a wholly owned subsidiary in India named Vivos Scientific India LLP, and is in the process of obtaining formal approvals from the Indian government [1] - The establishment of the subsidiary reflects Vivos's long-term commitment to the Indian market, aiming to set up its first international manufacturing center for RadioGel and IsoPet, and to expand developmental animal testing and commercial treatments in India [2] - Vivos has initiated first-in-human trials in India and is pursuing additional approvals for expanded human trials from the Drug Controller General of India (DCGI), which are believed to support the IDE process with the FDA [2] Company Strategy - The company plans to include immediate post-treatment PET full-body scans in the next phase of human trials in India to validate the safety profile of RadioGel, based on feedback from the FDA [2]

Core Points - Vivos Inc. has received authorization to establish a wholly owned subsidiary in India named Vivos Scientific India LLP, and is in the process of obtaining formal approvals from the Indian government [1] - The establishment of the subsidiary reflects Vivos Inc.'s long-term commitment to the Indian market, aiming to set up an international manufacturing center for RadioGel and IsoPet, and to expand developmental animal testing and commercial treatments for humans and animals in India [2] - Vivos Inc. has initiated first-in-human trials in India and is pursuing approval from the Drug Controller General of India (DCGI) for expanded human trials, which are expected to support the IDE process with the FDA [2] Company Strategy - The company plans to include immediate post-treatment PET full-body scans in the next phase of human trials in India to validate the safety profile of RadioGel, based on feedback from the FDA [2]